Printer Friendly

ROBERTS PHARMACEUTICAL REPORTS 1991 RESULTS

 ROBERTS PHARMACEUTICAL REPORTS 1991 RESULTS
 EATONTOWN, N.J., March 31 /PRNewswire/ -- Roberts Pharmaceutical


Corporation (NASDAQ: RPCX) reported today that total revenues for the year ended Dec. 31, 1991 were $14.2 million, representing an $11.2 million increase over the $3.0 million total revenue achieved in 1990. For the year 1991, product sales were $10.7 million; an increase of $9.5 million from the $1.2 million recorded in 1990. Prescription products accounted or $7.2 million or 67 percent of total product sales in 1991. Revenues for the fourth quarter of 1991 totalled $5.4 million compared with $1.6 million for the corresponding quarter in 1990.
 Roberts reported a net loss of $5.1 million for fiscal year 1991 which was $1.3 million less than the net loss of $6.4 million in 1990. The 1991 loss of $0.58 per share on 8.8 million average shares outstanding compares to the loss of $0.92 per share on 7.0 million average shares outstanding for 1990. The net loss of $940,000 for the quarter ended Dec. 31, 1991 was $1,150,000 or 45 percent less than the $2,090,000 loss incurred during the same quarter in 1990. The fourth quarter loss per common share was $0.09 per share on 10.0 million average shares outstanding as compared to $0.29 per share on 7.2 million average shares outstanding for the comparable period in 1990.
 As of Dec. 31, 1991, the company had total assets of $44.1 million with $14.2 million in cash and liquid investments compared with $16.3 million in total assets and $9.5 million in cash and liquid investments at year end 1990.
 Robert A. Vukovich, chairman and CEO, said: "Roberts strong sales achievement in 1991 provides an excellent base for substantially enhanced sales performance in 1992 as evidenced by our continuing increase in average monthly sales. Our year-end financial position is strong and has been significantly strengthened with the $95 million equity investment by Yamanouchi in the month of March 1992. Our 1991 performance and current financial strength indicates that Roberts has the operational structure and financial resources to continue to implement its plans and programs and to further accelerate its growth strategy."
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 ROBERTS PHARMACEUTICAL CORPORATION
 Summary Consolidated Financial Information
 (All amounts in thousands except per share data)
 Operating Statement Data
 Period ended Three months Year
 Dec. 31 1991 1990 1991 1990
 Revenues:
 Product sales $3,870 $ 976 $10,745 $1,200
 Licenses, interest
 and other 1,495 647 3,434 1,845
 Total 5,365 1,623 14,179 3,045
 Net income (loss) 941 2,090 (5,126) (6,358)
 Income (loss) per
 common share (.09) (.29) (.58) (.92)
 Weighted average common
 shares outstanding 9,955 7,174 8,843 7,033
 Balance Sheet Data
 Dec. 31 1991 1990
 Assets:
 Cash and marketable securities $14,161 $ 9,545
 Other current assets 5,600 2,217
 Other assets 24,389 4,558
 Total assets 44,150 16,320
 Liabilities & Stockholders equity:
 Current liabilities 9,807 3,133
 Long-term debt 9,237 5,842
 Stockholders' equity 25,106 7,345
 Total liabilities & stockholders' equity 44,150 16,320
 NOTE: In June 1991, Roberts changed its fiscal year from a fiscal
 year ending on June 30 to a fiscal year ending on December 31.
 -0- 3/31/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey IN: MTC SU: ERN


TQ-OS -- NY023 -- 3310 03/31/92 10:15 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 31, 1992
Words:652
Previous Article:SPRINT ANNOUNCES DIRECT VIDEO CONNECTIVITY TO EUROPE VIA SWISS PTT's MEGACOM NETWORK
Next Article:PAULSON CAPITAL REPORTS RECORD REVENUES AND EARNINGS FOR FISCAL 1991
Topics:


Related Articles
ROBERTS PHARMACEUTICALS ANNOUNCES THIRD QUARTER RESULTS
DURAMED-RESULTS CL008 /From PR Newswire in Cleveland at 216-566-7777/
ROBERTS PHARMACEUTICAL REPORTS RECORD LEVEL FIRST QUARTER SALES
DURAMED REPORTS FIRST QUARTER RESULTS FOR 1992
ROBERTS PHARMACEUTICAL ANNOUNCES SECOND QUARTER RESULTS
IVAX ANNOUNCES RECORD EARNINGS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES THIRD QUARTER RESULTS
IVAX ANNOUNCES A 233 PERCENT EARNINGS INCREASE
ROBERTS PHARMACEUTICAL CORPORATION REPORTS RECORD 1992 SALES RESULTS
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES RECORD 1993 SALES AND PROFITS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters